- Home
- UAMY vs BBOT Comparison
UAMY vs BBOT Comparison
Compare UAMY & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAMY | BBOT |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UAMY | BBOT |
|---|---|---|
| Price | $8.19 | $10.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.69 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 18.3M | 277.9K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,857,819.00 | N/A |
| Revenue This Year | $159.13 | N/A |
| Revenue Next Year | $228.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 177.97 | N/A |
| 52 Week Low | $1.21 | $8.50 |
| 52 Week High | $19.71 | $14.87 |
Technical Indicators
Market Signals| Indicator | UAMY | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 40.95 |
| Support Level | $7.35 | $10.08 |
| Resistance Level | $8.65 | $12.01 |
| Average True Range (ATR) | 1.33 | 0.93 |
| MACD | -0.20 | -0.19 |
| Stochastic Oscillator | 20.90 | 15.86 |
Price Performance
Historical ComparisonAbout UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.